Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2

Cancer Gene Therapy

Volumn 9, Issue 7, 2002, Pages 579-586

  Kowalski, Petra ^a   Stein, Ulrike ^b   Scheffer, George L ^c   Lage, Hermann ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atypical multidrug resistance; BCRP; Mitoxantrone gastric carcinoma; Ribozyme

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN DERIVATIVE; CANERTINIB; CISPLATIN; DAUNORUBICIN; DEMETHOXYFUMITREMORGIN C; ELACRIDAR; ETOPOSIDE; FUMITREMORGIN C; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BCRP; PROTEIN MXR; RIBOZYME; RIBOZYME RZB1; UNCLASSIFIED DRUG; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC ANTIBIOTIC; HAMMERHEAD RIBOZYME; MESSENGER RNA; PEPTIDE; TUMOR PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG SENSITIVITY; GENE THERAPY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; STOMACH CARCINOMA; TREATMENT FAILURE; CELL CULTURE; CELL DIVISION; CELL FREE SYSTEM; CELL SURVIVAL; DRUG RESISTANCE; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH TUMOR; TIME;

ANTIBIOTICS, ANTHRACYCLINE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; BASE SEQUENCE; CELL DIVISION; CELL SURVIVAL; CELL-FREE SYSTEM; CISPLATIN; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FLOW CYTOMETRY; HUMAN; MITOXANTRONE; MOLECULAR SEQUENCE DATA; PEPTIDES; PHENOTYPE; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, CATALYTIC; RNA, MESSENGER; STOMACH NEOPLASMS; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; ANTIBIOTICS, ANTINEOPLASTIC; HUMANS; NEOPLASM PROTEINS;

EID: 0036019374     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700471     Document Type: Article

References (36)

1. Multidrug resistance in cancer: Role of ATP-dependent transporters
2. A family of drug transporters: The multidrug resistance-associated proteins
3. Effect of the breast cancer resistance protein on atypical multidrug resistance
4. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines
5. A multidrug resistance transporter from human MCF-7 breast cancer cells
6. Multidrug resistance and its reversal
7. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein
8. Inhibition of BCRP-mediated drug efflux by fumitremorgintype indolyl diketopiperazines
9. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR
10. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux
11. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918
12. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line
13. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDRI(PGY1) ribozyme
14. Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme
15. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells
16. A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1
17. Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter
18. Sequence requirements of the hammerhead RNA self-cleavage reaction
19. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells
20. Selection and characterization of a high activity ribozyme directed against the antineoplastic drug resistance-associated ABC-transporter BCRP/MXR/ABCG2
21. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257
22. DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells
23. Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and MRP
24. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues
25. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines
26. New colorimetric cytotoxicity assay for anticancer-drug screening
27. The mouse Bcrp1/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin
28. Enhanced expression of human ABC-transporter TAP is associated with cellular resistance to mitoxantrone
29. Ribozymes correctly cleave a model substrate and endogenous RNA in vivo
30. Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides
31. Selection of a high activity ribozyme against the cytostatic drug resistance associated glypican-3 using an in vitro assay containing total tumor RNA
32. Kinetic characterization of ribozymes directed against the cisplatin resistance-associated ABC-transporter cMOAT/MRP2/ABCC3
33. Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein
34. Involvement of the DNA mismatch repair system in antineoplastic dug resistance
35. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype
36. Numbering system for the hammerhead